AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

1. (Cancelled)

2. (Currently amended) A vaccine composition comprising (a) an antigen and (b) an immunoadjuvant wherein said immunoadjuvant compound consists of a Rho GTPase activator selected from the group consisting of:

- a polypeptide comprising the amino acid sequence starting at the amino acid residue 720 and ending at the amino acid residue 1014 of sequence SEQ ID NO 1 [[,]] and

~~- a polypeptide comprising the amino acid sequence starting at the amino acid residue 720 and ending at the amino acid residue 1014 of sequence SEQ ID NO 2,~~

~~- a polypeptide comprising the amino acid sequence starting at the amino acid residue 720 and ending at the amino acid residue 1014 of sequence SEQ ID NO 3, and~~

- a polypeptide comprising the amino acid sequence starting at the amino acid residue 1146 and ending at the amino acid residue 1451 of sequence SEQ ID NO 4.

3. (Currently amended) [[A]] The vaccine composition according to claim 2 wherein said immunoadjuvant compound is selected from the group consisting of :

the cytotoxic necrotizing factor 1 (CNF1) of ~~a polypeptide comprising the amino acid sequence~~ SEQ ID NO 1[[,]]and

the dermonecrotic toxin (DNT) of ~~a polypeptide comprising the amino acid sequence~~ SEQ ID NO [[2]] 4.~~,~~

~~a polypeptide comprising the amino acid sequence SEQ ID NO 3, and~~

~~a polypeptide comprising the amino acid sequence SEQ ID NO 4.~~

4-7. (Cancelled)

8. (Currently amended) [[A]] The vaccine composition according any one of claims ~~1 to 4~~ 2 and 3 wherein the antigen is selected from the group consisting of a hormone, a protein, a drug, an enzyme, a vaccine composition against bacterial, viral, fungal, prion, or parasitic infections, a component produced by microorganisms, inactivated bacterial toxins such as cholera toxin, ST and LT from Escherichia coli[[,]] and tetanus toxin from Clostridium tetani~~, and proteins derived from HIV viruses~~.

9. (Currently amended) [[A]] The vaccine composition according any one of claims ~~1 to 4~~ 2 and 3 for administration to a mucosal surface.

10. (Currently amended) [[A]] The vaccine composition according any one of claims ~~1 to 4~~ 2 and 3 for an oral administration.

11-14. (Cancelled)

15. (Currently amended) A method for preparing a vaccine composition according to claim 2, comprising the step of:

adding [[the]]an immunoadjuvant~~ as defined in any one of claims 1 to 4~~ to an excipient, wherein

said immunoadjuvant consists of a Rho GTPase activator selected from the group consisting of:

a polypeptide comprising the amino acid sequence starting at the amino acid residue 720 and ending at the amino acid residue 1014 of sequence SEQ ID NO 1 and

a polypeptide comprising the amino acid sequence starting at the amino acid residue 1146 and ending at the amino acid residue 1451 of sequence SEQ ID NO 4.

16. (Cancelled)

17. (new) A method for preparing a vaccine composition according to claim 3, comprising the step of:

adding an immunoadjuvant to an excipient, wherein

said immunoadjuvant compound is selected from the group consisting of: the cytotoxic necrotizing factor 1 (CNF1) of SEQ ID NO 1 and the dermonecrotic toxin (DNT) of SEQ ID NO 4.